Skip to content
Buy This GLP
← Research
Evidence

Does Semaglutide Lower Your Risk From COVID-19 or Flu?

A SELECT trial analysis and a matched records study found fewer deaths after infection. The evidence for prevention and treatment is a separate question.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
30-day mortality after a recorded infectionPrior semaglutide above, metformin belowCOVID-190.3%0.8%Influenza0.2%0.7%Matched medical records study

What the randomized SELECT trial found

SELECT randomized 17,604 adults aged 45 or older to weekly semaglutide or placebo. They had established cardiovascular disease and overweight or obesity, without diabetes. The primary question was about major cardiovascular events. In a secondary analysis, COVID-19 occurred at similar rates in the two groups, but fewer participants in the semaglutide group died of COVID-19 (43 versus 65; hazard ratio 0.66, 95% CI 0.44 to 0.96) [1].

What can records tell us about flu and COVID-19?

A separate medical records study compared people who were already taking semaglutide after a documented infection with matched metformin users who had no prior GLP-1 treatment. There were 7,092 people per treatment group for COVID-19 and 1,920 per group for flu. Thirty-day all-cause mortality was 0.3% versus 0.8% after COVID-19 (risk ratio 0.39) and 0.2% versus 0.7% after flu (risk ratio 0.29, 95% CI 0.09 to 0.87) [2].

In each comparison, the difference was about five deaths per 1,000 people with a documented infection, based on the rounded rates. The study matched people on factors including vaccination history and antiviral use. Differences the researchers could not measure, such as frailty or how closely people followed treatment, could still affect the results.

What the studies leave open

Studies of GLP-1 drugs and markers of inflammation examine a possible explanation for better outcomes. The COVID-19 and influenza studies do not establish which biological changes, if any, account for the observed differences.

Both studies looked at people assigned or treated before infection, so they do not show whether starting semaglutide after getting sick helps.

Frequently asked

Does semaglutide help prevent COVID-19?
SELECT did not find that semaglutide reduced COVID-19 infections. A separate analysis within that trial found fewer COVID-19 deaths among adults with overweight or obesity and cardiovascular disease assigned semaglutide.
Does semaglutide treat influenza?
The flu study compared prior semaglutide users with prior metformin users after a documented infection. It did not test starting semaglutide as a treatment for flu.

Sources

  1. [1] Scirica BM, et al. (2024). The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial Journal of the American College of Cardiology. Source
  2. [2] Matson R, et al. (2026). Semaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection Biology Methods and Protocols. PMID 42540132

More in Evidence